S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Closing prices for crude oil, gold and other commodities
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Closing prices for crude oil, gold and other commodities
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Closing prices for crude oil, gold and other commodities
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Closing prices for crude oil, gold and other commodities
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion

IN8bio (INAB) Competitors

$0.95
-0.06 (-5.92%)
(As of 02/23/2024 ET)

INAB vs. INKT, PLUR, ENTX, APTO, SRZN, CRTX, DYAI, FRLN, ESLA, and NKGN

Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include MiNK Therapeutics (INKT), Pluri (PLUR), Entera Bio (ENTX), Aptose Biosciences (APTO), Surrozen (SRZN), Cortexyme (CRTX), Dyadic International (DYAI), Freeline Therapeutics (FRLN), Estrella Immunopharma (ESLA), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector.

IN8bio vs.

MiNK Therapeutics (NASDAQ:INKT) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

1.4% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 7.4% of IN8bio shares are held by institutional investors. 17.8% of MiNK Therapeutics shares are held by company insiders. Comparatively, 33.0% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MiNK Therapeutics has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500.

MiNK Therapeutics currently has a consensus price target of $6.50, suggesting a potential upside of 622.22%. IN8bio has a consensus price target of $11.00, suggesting a potential upside of 1,054.25%. Given MiNK Therapeutics' higher probable upside, analysts plainly believe IN8bio is more favorable than MiNK Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
IN8bio
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

IN8bio received 7 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. However, 64.29% of users gave MiNK Therapeutics an outperform vote while only 64.00% of users gave IN8bio an outperform vote.

CompanyUnderperformOutperform
MiNK TherapeuticsOutperform Votes
9
64.29%
Underperform Votes
5
35.71%
IN8bioOutperform Votes
16
64.00%
Underperform Votes
9
36.00%

In the previous week, MiNK Therapeutics had 1 more articles in the media than IN8bio. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for IN8bio. MiNK Therapeutics' average media sentiment score of 0.00 beat IN8bio's score of -1.32 indicating that IN8bio is being referred to more favorably in the news media.

Company Overall Sentiment
MiNK Therapeutics Negative
IN8bio Neutral

IN8bio's return on equity of 0.00% beat MiNK Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -171.90%
IN8bio N/A -152.81%-106.33%

MiNK Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$27.99M-$0.73-1.23
IN8bioN/AN/A-$28.52M-$1.12-0.85

Summary

MiNK Therapeutics and IN8bio tied by winning 7 of the 14 factors compared between the two stocks.


Get IN8bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INAB vs. The Competition

MetricIN8bioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$30.49M$2.75B$5.10B$7.53B
Dividend YieldN/A2.36%2.86%3.87%
P/E Ratio-0.854.86176.0015.16
Price / SalesN/A307.043,048.5867.59
Price / CashN/A27.9798.6255.40
Price / Book1.024.054.394.60
Net Income-$28.52M$59.66M$113.02M$207.29M
7 Day Performance-14.14%-0.17%0.91%-1.07%
1 Month Performance-27.25%10.43%7.27%3.57%
1 Year Performance-34.73%8.88%10.67%5.52%

IN8bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INKT
MiNK Therapeutics
1.4151 of 5 stars
$0.94
+2.2%
$6.50
+592.3%
-57.4%$32.41MN/A-1.2937Negative News
Gap Up
PLUR
Pluri
0 of 5 stars
$0.78
-6.0%
N/A-24.5%$32.35M$357,000.00-1.34123News Coverage
Gap Down
ENTX
Entera Bio
1.8469 of 5 stars
$1.07
+1.9%
$10.00
+834.6%
+9.4%$30.82M$130,000.00-3.1519
APTO
Aptose Biosciences
1.484 of 5 stars
$1.95
flat
$36.50
+1,771.8%
-81.2%$29.19MN/A-0.2531Gap Up
SRZN
Surrozen
0 of 5 stars
$13.99
+17.9%
N/A-20.1%$28.54M$12.50M-0.8074Positive News
CRTX
Cortexyme
0 of 5 stars
$1.28
-1.5%
N/A+29.1%$38.59MN/A-0.4355News Coverage
DYAI
Dyadic International
1.8502 of 5 stars
$1.34
+1.5%
$6.00
+347.8%
+7.0%$38.61M$2.93M-5.837News Coverage
Positive News
FRLN
Freeline Therapeutics
2.1063 of 5 stars
$6.48
flat
$11.13
+71.7%
N/A$28.12MN/A-1.16152
ESLA
Estrella Immunopharma
0 of 5 stars
$1.06
-3.6%
N/AN/A$38.81MN/A0.00N/APositive News
Gap Down
NKGN
NKGen Biotech
0 of 5 stars
$1.26
-16.0%
N/AN/A$27.58MN/A0.00N/AUpcoming Earnings
News Coverage

Related Companies and Tools

This page (NASDAQ:INAB) was last updated on 2/24/2024 by MarketBeat.com Staff